Update on the medical treatment of Graves’ ophthalmopathy
Gregory J Griepentrog, James A Garrity
Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA
Purpose: To review recent advances in the understanding of Graves’ ophthalmopathy (GO) pathogenesis as well as discuss current and future medical management strategies.
Design: Interpretive essay.
Methods: Literature review and interpretation.
Results: Medical treatment of GO has slowly evolved during the past few decades and has been hampered by a poor understanding of the disease at a cellular and molecular level. Current treatment recommendations and guidelines therefore focus on nonspecific immuno-suppression. Newer classes of treatment agents hold promise to more selectively target underlying cellular and molecular alterations in GO.
Conclusion: Cooperation between individual patients, physicians and between differing medical centers, together with a refined understanding of the pathogenesis of GO, will lead to newer more-effective treatments for the disease and improve patient quality of life.
Keywords: Graves’ ophthalmopathy, thyroid eye disease, thyroid-associated ophthalmopathy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]